Canopy Growth (NASDAQ:CGC – Get Free Report) and Nephros (NASDAQ:NEPH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Valuation and Earnings
This table compares Canopy Growth and Nephros”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Canopy Growth | $225.65 million | 1.83 | -$429.86 million | ($1.30) | -0.78 |
| Nephros | $18.79 million | 1.88 | $1.19 million | $0.07 | 46.43 |
Risk & Volatility
Canopy Growth has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Canopy Growth and Nephros, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Canopy Growth | 1 | 3 | 2 | 0 | 2.17 |
| Nephros | 0 | 1 | 1 | 0 | 2.50 |
Nephros has a consensus target price of $6.00, suggesting a potential upside of 84.62%. Given Nephros’ stronger consensus rating and higher possible upside, analysts clearly believe Nephros is more favorable than Canopy Growth.
Profitability
This table compares Canopy Growth and Nephros’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Canopy Growth | -94.39% | -46.85% | -28.95% |
| Nephros | 4.06% | 7.66% | 5.86% |
Institutional and Insider Ownership
3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Comparatively, 6.7% of Nephros shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Nephros beats Canopy Growth on 12 of the 14 factors compared between the two stocks.
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
